Epigenetic modulation in sensitizing metastatic sarcomas to therapies and overcoming resistance
作者机构：Department of Internal MedicineUniversity of IowaIowa CityIA 52242USA Holden Comprehensive Cancer CenterUniversity of IowaIowa CityIA 52242USA
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2022年第5卷第1期
页 面：25-35页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：National Heart Lung and Blood Institute [T32HL007344] Funding Source: NIH RePORTER
主 题：Epigenetics sarcoma resistance metastasis
摘 要：Sarcomas are a class of rare malignancies of mesenchymal origin with a heterogeneous histological *** are classically associated with poor outcomes,especially once metastasized.A path to improving clinical outcomes may be made through modifying the epigenome,where a variety of sarcomas demonstrate changes that contribute to their oncogenic *** Perspective article identifies and describes changes in the sarcoma genome,while discussing specific epigenetic changes and their effect on clinical *** attempts at modulating epigenetics in sarcoma are reviewed,as well as potential implications of these *** targets to reverse and delay chemotherapy resistance are *** directions with primary next steps are proposed to invigorate the current understanding of epigenetic biomarkers to enact targeted therapies to epigenetic phenotypes of sarcoma *** to prior studies,as well as proposed clinical steps,are also addressed.
维普期刊数据库